- Companies
- AQEMIA
AQEMIA Funding, Investors & Competitors
AQEMIA has raised $103M across 5 funding rounds, most recently a $38M Series A in December 2024.
Last AQEMIA funding round
$38M
Series A · Dec 2024
Cumulative funding AQEMIA raised
$103M
across 5 funding rounds
Key investors in AQEMIA
Elaia
Eurazeo
Bpifrance
Wendel Growth
Cathay Innovation
Bpifrance Large Venture
About AQEMIA
AQEMIA is a Paris-based pharmatech firm leveraging a hybrid platform of generative AI and quantum physics simulations for drug discovery. It generates novel small molecules for oncology, immunology, and neurology targets. Since 2019, the company has advanced multiple candidates into preclinical stages with partnerships from Sanofi.
Founded
2019
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Licensing, Subscription
AQEMIA Funding History
AQEMIA has raised a total of $103M across 5 funding rounds.
AQEMIA's first fundraising round was a $1M pre-seed round in October 2019. The most recent completed round was a $38M Series A in December 2024.
AQEMIA funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Dec 2024 | Series A | Cathay Innovation (lead); Elaia; Bpifrance Large Venture; Eurazeo; Wendel Growth | $38M | AQEMIA is a Paris-based techbio company developing an AI-driven drug discovery platform that combines quantum-inspired atomic-scale physics with generative AI to design innovative therapeutic molecules more rapidly, without relying on experimental data for AI training. The platform has shown validation through internal preclinical programs and partnerships, especially in oncology, including a $140 million collaboration with Sanofi announced in December 2023. On December 10, 2024 (aligned with the approximate date of 10/12/2024), AQEMIA raised $38 million in a funding round led by Cathay Innovation, with participation from existing investors Wendel Growth, Bpifrance Large Venture, Eurazeo, and Elaia. This round brings the company's total funding since inception to over $100 million, following a €30 million raise in January 2024 that completed its €60 million Series A. The funds will support preparations for clinical trials, platform advancement, recruitment, and global expansion starting with a new London office opening in January 2025 to access UK talent. CEO Maximilien Levesque described it as a transformative moment, emphasizing acceleration toward clinical stages and international growth with Cathay's expertise in the US and Asia. Investors highlight AQEMIA's potential to reshape drug discovery by addressing inefficiencies in traditional methods, with Cathay Innovation's Jacky Abitbol noting alignment with their focus on AI in healthcare. The rapid follow-on funding signals strong market confidence amid the hot AI drug discovery sector. |
| Jan 2024 | Series A | Wendel Growth (lead); Elaia; Bpifrance; Eurazeo | $33M | AQEMIA is a Paris-based techbio company that combines atomic-scale quantum-inspired physics with generative artificial intelligence to accelerate drug discovery and design innovative therapeutic molecules. The platform overcomes data scarcity challenges in drug discovery by directly simulating molecular behavior rather than requiring experimental training data, enabling the exploration of entirely new molecular designs beyond existing structures. Unlike traditional generative AI approaches in drug discovery, AQEMIA's system achieves high computational efficiency without requiring supercomputers, enabling evaluation of hundreds of millions of molecules per iteration. On January 30, 2024, AQEMIA announced a €30 million Series A extension, bringing its total Series A funding to €60 million. The round was led by Wendel Growth and included participation from historical investors Bpifrance Large Venture, Eurazeo, and Elaia. The funding was announced to accelerate AQEMIA's drug discovery programs, build a stronger pipeline beyond projects already tested in animals, and develop the company's generative AI and physics-based platform for small molecule drug discovery. At the time of this round, AQEMIA had demonstrated traction through recent successes in internal pipeline projects and collaborative drug discovery work with pharmaceutical companies. The company had also recently secured a significant $140 million drug discovery partnership with Sanofi, validating its technology platform's potential in the market. The internal pipeline was focused primarily on oncology and immuno-oncology applications. Less than a year after this January 2024 round, AQEMIA raised an additional $38 million in December 2024 led by new investor Cathay Innovation, bringing cumulative funding to over $100 million. This subsequent round reflected continued validation of the platform through successful preclinical programs and pharmaceutical partnerships, with funds directed toward preparation for clinical trials and global expansion, including opening a new office in London in January 2025. |
| Oct 2022 | Series A | Bpifrance (lead); Elaia; Eurazeo | $20M | AQEMIA is a Paris-based biotech startup founded in 2019 that develops novel drug candidates for critical diseases, particularly in oncology and immuno-oncology, using a proprietary platform combining quantum-inspired physics, statistical mechanics, and generative AI to predict molecular interactions and accelerate drug discovery. The company has launched a proprietary pipeline of drug discovery projects ranging from in vitro to in vivo phases and collaborates with large pharmaceutical companies to generate innovative chemical matter. AQEMIA maintains offices in Paris and London, advancing RNA-targeting and protein-targeting programs toward clinical trials. On October 19, 2022, AQEMIA raised €30 million in a Series A funding round co-led by Eurazeo and Bpifrance through its Large Venture fund, with participation from historic investor Elaia. The financing supports scaling the drug discovery platform and proprietary therapeutic assets, with an initial focus on oncology and immuno-oncology. The funds enable AQEMIA to build a massive pipeline of wholly-owned projects following successes in partnerships. Bpifrance and Eurazeo highlighted the potential of AQEMIA's deep physics and AI engine to improve early drug discovery outcomes. |
| May 2021 | Series A | Eurazeo (lead); Elaia | $11M | AQEMIA is a Paris-based deeptech biotech company specializing in AI-powered drug discovery, leveraging quantum-inspired physics and machine learning to generate novel chemical materials and drug candidates, particularly in oncology and immuno-oncology. The company collaborates with large pharmaceutical firms and maintains an internal pipeline of therapeutic assets. In January 2021, AQEMIA raised approximately $10.2 million (equivalent to about €8.4 million) from investors Eurazeo and Elaia, marking an early funding round ahead of its Series A. This investment supported the startup's technology development and drug discovery efforts. At that time, AQEMIA had demonstrated successes in generating novel chemical materials through collaborations with global pharmaceutical companies. Subsequently, in October 2022, AQEMIA raised €30 million in an initial Series A tranche co-led by Eurazeo and Bpifrance Large Venture, with participation from Elaia, followed by a €30 million extension led by Wendel Growth, bringing the total Series A to €60 million. Later, in 2024, AQEMIA secured an additional $38 million round led by Cathay Innovation, with returning investors including Eurazeo and Elaia, pushing cumulative funding past $100 million to advance preclinical programs toward clinical trials and expand globally, including a new London office. |
| Oct 2019 | Pre-seed | Elaia (lead) | $1M | - |
Who has invested in AQEMIA?
6 investors have backed AQEMIA across its funding rounds, including Elaia, Eurazeo, Bpifrance, Wendel Growth, Cathay Innovation and Bpifrance Large Venture.
Lead investors include Cathay Innovation, Wendel Growth, Bpifrance, Eurazeo and Elaia.
AQEMIA Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 5 | Lead | Oct 2019 | ||
| 4 | Lead | May 2021 | ||
| 2 | Lead | Oct 2022 | ||
| 2 | Lead | Jan 2024 | ||
This data is available for Pro users. Sign up to see all 6 AQEMIA investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAQEMIA Competitors
AQEMIA competitors include listed companies like SAP and Snowflake, and private ones like Quantum Systems, SandboxAQ, Astromech and Chai Discovery.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $330M | - | $8B | 24.2x | ||
| Private | - | - | $5.8B | - | ||
| Private | - | - | $3.8B | - | ||
| Private | $48M | - | $3.8B | - | ||
| Publicly listed | $42B | $13B | $248B | 5.4x | ||
| Publicly listed | $4.7B | ($1.3B) | $119B | 21.0x |
AQEMIA Public Comps
AQEMIA is still privately-owned, but its public comps include Eli Lilly, Johnson & Johnson, AbbVie, Merck, Roche, Novartis, AstraZeneca, CrowdStrike, SAP and Amgen.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $65B | $28B | 16.5x | 13.1x | 38.7x | 27.0x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $61B | $17B | 8.7x | 8.1x | 30.6x | 17.6x | |||
| $65B | $28B | 6.3x | 6.2x | 14.7x | 21.0x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $57B | $22B | 5.5x | 5.5x | 14.2x | 13.3x | |||
| $59B | $19B | 4.8x | 4.5x | 14.6x | 12.7x | |||
| $4.8B | ($12M) | 51.4x | 44.5x | (19816.2x) | 151.0x | |||
This data is available for Pro users. Sign up to see all AQEMIA competitors and their valuation data. Start Free Trial | ||||||||
Common questions about AQEMIA
| When was AQEMIA founded? | AQEMIA was founded in 2019. |
| Where is AQEMIA headquartered? | AQEMIA is headquartered in Paris, France. |
| Is AQEMIA publicly listed? | No, AQEMIA is a private, VC-backed company. |
| How much funding has AQEMIA raised? | AQEMIA has raised $103M across 5 funding rounds. |
| What was AQEMIA's last funding round? | AQEMIA's last funding round was a $38M Series A in December 2024, led by Cathay Innovation. |
| Who are AQEMIA's investors? | AQEMIA's investors include Elaia, Eurazeo, Bpifrance, Wendel Growth, Bpifrance Large Venture and Cathay Innovation. |
| Which companies are comparable to AQEMIA? | Companies comparable to AQEMIA include Quantum Systems, SandboxAQ, Astromech, Chai Discovery, SAP and Snowflake. |
See companies similar to AQEMIA
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




